We first compared the efficacy of three MEK inhibitors (trametinib, cobimetinib, and binimetinib) combined with anti‐EGFR antibodies in two randomly chosen KRAS mutated CRC PDX models in vivo, which have previously shown effective in vitro. This evidence concerns the gene MAP2K7 and colorectal carcinoma.